HCV therapy reduces work loss and costs due to lost productivity

  • PDF / 186,069 Bytes
  • 1 Pages / 595.245 x 841.846 pts (A4) Page_size
  • 37 Downloads / 160 Views

DOWNLOAD

REPORT


PharmacoEconomics & Outcomes News 863, p17 - 3 Oct 2020 HCV therapy reduces work loss and costs due to lost productivity Treatment of chronic hepatitis C virus (HCV) infection reduces health-related work loss and costs associated with lost productivity, according to findings of an AbbVie-funded study published in Advances in Therapy. Data from Optum Healthcare Solutions (1999–March 2017) were used to evaluate work-loss events and costs of lost productivity in privately insured adults (18–65 years) with newly-diagnosed HCV who received curative HCV therapy with interferon and/or direct-acting antivirals (DAAs), compared with untreated patients. Time-to-event analysis was used to assess the time from index date (end of the post-treatment monitoring period; 6 months in patients with cirrhosis or treated with interferon-based therapy, and 3 months in patients without cirrhosis treated with interferonfree therapy) to first work-loss event. Economic modelling was used to assess the monetary value of improved productivity associated with the reduced risk of a work-loss event during the 4-year follow-up period after the index date. The risk of a health-related work-loss event was significantly lower in treated patients than in untreated patients (adjusted hazard ratio 0.68; 95% CI 0.55, 0.85; p